U.S. markets close in 3 hours 37 minutes
  • S&P 500

    4,397.06
    +1.80 (+0.04%)
     
  • Dow 30

    34,921.64
    -13.83 (-0.04%)
     
  • Nasdaq

    14,716.10
    +43.42 (+0.30%)
     
  • Russell 2000

    2,224.29
    -1.95 (-0.09%)
     
  • Crude Oil

    71.11
    -2.84 (-3.84%)
     
  • Gold

    1,819.20
    +2.00 (+0.11%)
     
  • Silver

    25.49
    -0.06 (-0.22%)
     
  • EUR/USD

    1.1874
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.1560
    -0.0830 (-6.70%)
     
  • GBP/USD

    1.3880
    -0.0026 (-0.19%)
     
  • USD/JPY

    109.2010
    -0.4140 (-0.38%)
     
  • BTC-USD

    39,893.70
    -985.38 (-2.41%)
     
  • CMC Crypto 200

    975.20
    +14.30 (+1.49%)
     
  • FTSE 100

    7,081.72
    +49.42 (+0.70%)
     
  • Nikkei 225

    27,781.02
    +497.43 (+1.82%)
     

Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) Nurtec ODT (rimegepant) orally disintegrating tablet (ODT) patients take every other day.

  • Enrolling will start later this year.

  • The primary endpoint will be a 50% reduction in the number of headache days patients experience per month versus Nurtec ODT.

  • Both drugs are designed to target calcitonin gene-related peptide (CGRP), a protein in the brain that's thought to play a key role in migraines, Lilly said.

  • However, Lilly's drug binds to CGRP to prevent it from attaching to receptors, while Biohaven's Nurtec ODT blocks the receptor.

  • Nurtec ODT received approval in May and is the only drug that boasts FDA approvals to prevent and immediately treat migraines.

  • Meanwhile, Emgality is approved to prevent migraines and episodic cluster headaches in adults.

  • Price Action: LLY shares are down 1.37% at 223, and BHVN is down 6.39% at $94.04 during the market trading session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.